Clinical trial
Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients…
NCT00316563 · Alberta Health services, Other · Completed
Key facts
| NCT number | NCT00316563 |
|---|---|
| Title | Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study |
| Official title | A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study |
| Lead sponsor | Alberta Health services, Other |
| Collaborators | University of Alberta |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Anorexia, Taste Disorders, Olfactory Disorders |
| Intervention type | Drug, Other |
| Interventions | Marinol (Dronabinol), Placebo |
| Enrollment | 80 |
| Start date | Aug 1, 2006 |
| Completion | Nov 1, 2009 |
| First posted | Apr 21, 2006 |
| Last update posted | Feb 9, 2010 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: